Nutrition composition for nutrition support of liver cancer patients, nutrition support product and application

Abstract

The invention provides a nutrition composition for nutrition support of liver cancer patients, a nutrition support product and application, and belongs to the technical field of nutrition support compositions. The nutritional composition comprises the following components: valine, lysine, peanut peptide powder, mung bean peptide powder, whey protein powder, maltodextrin, black rice flour, resistant dextrin, soybean lecithin, medium chain triglyceride, composite vitamins, composite minerals, selenium yeast powder, a gardenia extract, ginkgo powder and a lucid ganoderma extract. Compared with the prior art, the nutritional composition provided by the invention has the advantages that by adjusting the components and proportions of the basic nutrient substances, the regulatory nutrient substances and the functional nutrient substances, the weight of a rat with liver cancer cachexia is effectively increased, the concentration of serum albumin and hemoglobin is increased, and the cachexia symptom of the rat with liver cancer is relieved.

Description

[0001] The present invention claims the priority of the Chinese patent application filed with the Chinese Patent Office on October 18, 2024, with application number 2024114591759, and invention name “A nutritional composition, nutritional support product and application for nutritional support of liver cancer patients”, the entire contents of which are incorporated by reference in the application. Technical Field

[0002] The present invention belongs to the technical field of nutritional support compositions, and relates to a nutritional composition, a nutritional support product and an application thereof for nutritional support of liver cancer patients. Background Art

[0003] The liver is the largest gland in the human body, and has the functions of supporting the body's metabolism, secreting and excreting bile, detoxifying, and regulating coagulation-anticoagulation. The metabolism of multiple vitamins, hormone metabolism, and the regulation of internal environment homeostasis depend on liver function. Therefore, when a disease occurs in the liver, especially in the course of severe liver diseases such as cirrhosis and liver cancer, on the one hand, the digestion, absorption, and utilization of various nutrients are reduced due to reduced liver function. On the other hand, during the treatment of patients, especially those undergoing surgical resection, interventional therapy, radiotherapy, and systemic drug therapy, they lose appetite and become emaciated. Some patients also have diarrhea, and malnutrition is often further aggravated by the influence of treatment factors. Therefore, nutritional support for patients in the course of liver cancer, especially those with liver cancer cachexia, is of great significance.

[0004] Chinese patent application 201910584629.8 provides a complete nutritional composition for improving liver function and liver fibrosis, including: basic nutrients, regulatory nutrients and functional nutrients; the basic nutrients include protein nutrients, carbohydrate nutrients, and lipid nutrients; the regulatory nutrients include complex vitamins and complex minerals, oligoxylose and fungal extracts; the functional nutrients include liver peptide powder and Poria extract. Compared with the prior art, this technology improves the defense capability of the liver immune system through the synergistic effect of basic nutrients and regulatory nutrients; promotes liver cell repair and regeneration through the synergistic effect of basic nutrients and functional nutrients; and finally achieves the improvement of human liver function through the synergistic effect of each component among the three, thereby significantly improving the nutritional status of patients with chronic liver disease and early cirrhosis, and contributing to the recovery of chronic liver disease and the reversal of liver fibrosis.

[0005] Chinese patent application 201611033364.5 provides a nutritional composition for treating liver cirrhosis and a preparation method thereof, wherein the nutritional composition is composed of the following parts by weight: 5-50 parts of concentrated whey protein, 5-50 parts of isolated soy protein, 1-5 parts of corn oligopeptides, 2-5 parts of phospholipids, 5-50 parts of maltodextrin, 1-20 parts of inulin, 1-3 parts of Antrodia camphorata extract, 1-5 parts of taurine, 1-4 parts of valine, 1-6 parts of leucine, 1-4 parts of isoleucine, 1-4 parts of arginine, 1-4 parts of reduced glutathione, 0.01-0.2 parts of complex minerals, and 0.05-0.1 parts of complex vitamins. This technology improves the nutritional metabolic state of patients with liver disease, promotes liver cell regeneration, and promotes the recovery of liver function through reasonable nutritional intervention, and can effectively improve the biochemical indicators and Child-Pugh scores of patients with liver cirrhosis and improve their quality of life.

[0006] Chinese patent application 201610332240.0 provides a special medical formula food suitable for patients with liver disease. Every 100g of the special medical formula food contains: 10-20g of soy protein peptide, 0.25-0.3g of α-linolenic acid, 5-8g of medium chain triglycerides, 6-9g of vegetable oil powder, 8-16g of sucrose, 14-22g of oligofructose, 15-25g of dietary fiber, 1.4-2g of minerals, and 30.3-40mg of vitamins.

[0007] However, the prior art cannot provide a more effective nutritional composition to fully support the nutritional status of people with liver cancer cachexia. Summary of the invention

[0008] In view of this, in view of the problem that the prior art cannot provide a more effective nutritional composition to fully support the nutritional status of people with liver cancer cachexia, the purpose of the present invention is to provide a nutritional composition, nutritional support product and application for nutritional support of liver cancer patients.

[0009] To achieve the above object of the invention, the present invention provides a nutritional composition comprising the following ingredients:

[0010] Valine, lysine, peanut peptide powder, mung bean peptide powder, whey protein powder, maltodextrin, black rice powder, resistant dextrin, soy lecithin, medium chain triglycerides, multivitamins, multiminerals, selenium yeast powder, gardenia extract, ginkgo powder and ganoderma extract.

[0011] Preferably, the nutritional composition comprises the following ingredients by mass:

[0012] 3.1-3.5 parts of valine, 0.8-1.2 parts of lysine, 1.6-2.4 parts of peanut peptide powder, 1.6-2.4 parts of mung bean peptide powder, 28-42 parts of whey protein powder, 14-19.6 parts of maltodextrin, 7-9.8 parts of black rice powder, 14-19.6 parts of resistant dextrin, 2-3 parts of soybean lecithin, 2-3 parts of medium-chain triglycerides, 0.6-0.8 parts of complex vitamins, 0.9-1.1 parts of complex minerals, 0.5-1.5 parts of selenium yeast powder, 1-3 parts of gardenia extract, 0.5-1.5 parts of ginkgo powder and 1-3 parts of ganoderma lucidum extract.

[0013] Preferably, the complex vitamin is a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C;

[0014] Preferably, the composite mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate.

[0015] More preferably, the nutritional composition comprises the following ingredients by mass:

[0016] 3.2-3.4 parts of valine, 0.9-1.1 parts of lysine, 1.8-2.2 parts of peanut peptide powder, 1.8-2.2 parts of mung bean peptide powder, 32-38 parts of whey protein powder, 15.6-18 parts of maltodextrin, 7.8-9 parts of black rice flour, 15.6-18 parts of resistant dextrin, 2.2-2.8 parts of soybean lecithin, 2.2-2.8 parts of medium-chain triglycerides, 0.65-0.75 parts of complex vitamins, 0.95-1.05 parts of complex minerals, 0.75-1.25 parts of selenium yeast powder, 1.5-2.5 parts of gardenia extract, 0.75-1.25 parts of ginkgo powder and 1.5-2.5 parts of ganoderma lucidum extract.

[0017] More preferably, the nutritional composition comprises the following ingredients by mass:

[0018] 3.3 parts of valine, 1 part of lysine, 2 parts of peanut peptide powder, 2 parts of mung bean peptide powder, 35 parts of whey protein powder, 16.8 parts of maltodextrin, 8.4 parts of black rice powder, 16.8 parts of resistant dextrin, 2.5 parts of soybean lecithin, 2.5 parts of medium-chain triglycerides, 0.7 parts of multivitamins, 1 part of multiminerals, 1 part of selenium yeast powder, 2 parts of gardenia extract, 1 part of ginkgo powder and 2 parts of ganoderma lucidum extract.

[0019] The ganoderma lucidum extract may be a commercially available product, or may be an extract obtained by extracting fruiting body slices and / or spore powder of the traditional Chinese medicine ganoderma lucidum.

[0020] Preferably, the preparation method of the Ganoderma lucidum extract comprises the following steps:

[0021] S1, mixing Ganoderma lucidum with water, refluxing for extraction, and filtering to obtain filtrate A and filter residue A;

[0022] S2, mixing the filter residue A with tetrahydrofuran, reflux extraction, and filtering to obtain filtrate B and filter residue B;

[0023] S3, subjecting the filter residue B obtained in step S2 to ethanol-water gradient extraction, and combining the filtrates obtained by the gradient extraction to obtain filtrate C;

[0024] S4, combining the filtrate A obtained in step S1, the filtrate B obtained in step S2 and the filtrate C obtained in step S3, concentrating and drying to obtain a Ganoderma lucidum extract.

[0025] Preferably, the method for preparing the gardenia extract comprises the following steps:

[0026] The gardenia is crushed, mixed with 1-2 times the weight of water, simmered for 2-3 hours, filtered, and the filtrate is freeze-dried to obtain freeze-dried powder of the filtrate. 10% of the weight of the filter residue is freeze-dried and ground into powder, and mixed with the freeze-dried powder of the filtrate to obtain the gardenia extract.

[0027] Preferably, the complex vitamin is a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C in a mass ratio of 18-20:0.01-0.05:130:20-30:20-30:20-30:250:4:60:1900-2000.

[0028] Preferably, the composite mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate in a mass ratio of 1:2-3:1-2.

[0029] In another aspect, the present invention provides a nutritional support product prepared using the above nutritional composition as a raw material.

[0030] The types of products include, but are not limited to, complete nutrition products, incomplete nutrition products, dietary supplements, special prescription diets, health products, products that are both medicine and food, and foods containing the above products.

[0031] The dosage form of the product includes, but is not limited to, a dosage form taken in a solid form and a dosage form taken in a liquid form. The dosage form taken in a solid form includes nutrition bars, nutrition blocks, nutrition tablets, nutrition balls, etc., and also includes a form combined with any existing solid form of food, such as nutrition biscuits, nutrition noodles, nutrition tablet candies, nutrition cakes, etc. The dosage form taken in a liquid form includes nutrition emulsions, nutrition oral liquids, etc., and also includes a form combined with any existing liquid form and / or solid-liquid mixed form of food, such as nutrition milk tea, nutrition milk shakes, nutrition sorbet, nutrition rice paste, etc., and also includes a form that can be mixed with an appropriate liquid solvent to obtain a liquid dosage form, such as nutrition milk powder, nutrition instant powder, nutrition protein powder, nutrition granules, etc.

[0032] Preferably, the dosage form of the nutritional support product is a powder.

[0033] In still another aspect, the present invention provides use of the above nutritional composition in producing a product for nutritional support of liver cancer patients.

[0034] Compared with the prior art, the present invention has the following beneficial effects:

[0035] (1) The present invention provides a novel nutritional composition. By scientifically proportioning the components and amounts of protein nutrients, carbohydrate nutrients, and lipid nutrients, and reconstructing the components and proportions of regulatory nutrients and functional nutrients, a nutritional composition that more effectively supports the nutritional status of patients with liver cancer cachexia is obtained.

[0036] (2) Animal experiments show that compared with conventional foods and food compositions provided by the prior art, the nutritional composition provided by the present invention has a stronger nutritional support effect on rats with liver cancer cachexia. While effectively maintaining the weight of the rats, it can effectively increase the concentrations of hemoglobin and albumin in the serum, thereby helping to improve the quality of life of the rats. DETAILED DESCRIPTION

[0037] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of the present invention, and those skilled in the art can make various changes and modifications to the present invention based on the disclosed content, which should also fall within the scope of the present invention.

[0038] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. Unless otherwise specified, the contents described below are all weight contents. Unless otherwise specified, it is understood that the process is carried out at room temperature.

[0039] The following reagents used in the specific embodiments of the present invention are all commercially available, and their specifications are shown in the following table:

[0040]

[0041]

[0042] Example 1-5 provides a nutritional composition, the composition and weight percentage of each component are shown in the following table:

[0043]

[0044] In Examples 1-5, the complex vitamin is a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C in a mass ratio of 20:0.05:130:30:30:30:250:4:60:1900; the complex mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate in a mass ratio of 1:3:1.

[0045] In Examples 1-5, the preparation method of the Ganoderma lucidum extract used is as follows:

[0046] (1) Ganoderma lucidum fruiting bodies are crushed into Ganoderma lucidum particles with a particle size of 0.1-1 cm.

[0047] (2) Organic solvent extraction: The obtained Ganoderma lucidum particles were mixed with 7 times the mass of tetrahydrofuran, refluxed for 2.5 hours, and filtered. Repeated twice and the filtrates were combined.

[0048] (3) Ethanol-water gradient extraction: The residue obtained by organic solvent extraction was mixed with 7 times the mass of ethanol, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of 75% ethanol aqueous solution, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of 40% ethanol aqueous solution, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of water, refluxed for 4 h, and the extraction with water was repeated twice. The filtrates were combined.

[0049] (4) combining all the filtrates obtained in the two steps of "organic solvent extraction" and "ethanol-water gradient extraction", standing to break the emulsion, and concentrating by rotary evaporation to recover the solvent. After concentrating until there is no alcohol taste, freeze-drying is performed to obtain the Ganoderma lucidum extract.

[0050] In Examples 1-5, the preparation method of the Gardenia jasminoides extract used is as follows:

[0051] The gardenia was crushed into particles with a diameter of 1-5 mm, fully moistened and mixed with 2 times the weight of water, simmered and steamed for 3 hours, filtered, and the filtrate was freeze-dried to obtain lyophilized powder of the filtrate. 10% of the weight of the filter residue was freeze-dried and ground into powder, and mixed with the lyophilized powder of the filtrate to obtain the gardenia extract.

[0052] Example 6

[0053] Compared with Example 1, the composite mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate in a mass ratio of 1:2:2, and the rest are the same.

[0054] Example 7

[0055] Compared with Example 1, the complex vitamin is a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C in a mass ratio of 18:0.01:130:20:20:20:250:4:60:2000, and the rest are the same.

[0056] Example 8

[0057] Compared with Example 1, in the method for preparing the Ganoderma lucidum extract, step (3) is changed to the following:

[0058] (3) Ethanol-water gradient extraction: The filter residue obtained by ethyl acetate extraction was mixed with 7 times the mass of ethanol, refluxed for 3 h, and filtered; the filter residue was mixed with 7 times the mass of 65% ethanol aqueous solution, refluxed for 2 h, and filtered; the filter residue was mixed with 7 times the mass of 30% ethanol aqueous solution, refluxed for 3 h, and filtered; the filter residue was mixed with 7 times the mass of water, refluxed for 3 h, and the extraction with water was repeated twice.

[0059] The filtrates were combined;

[0060] The rest are the same.

[0061] In Comparative Examples 1-7, the components of the nutritional composition and their mass ratios are summarized in the following table ("-" means that the component is not contained):

[0062]

[0063] In Comparative Examples 1-7, the complex vitamins are a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C in a mass ratio of 20:0.05:130:30:30:30:250:4:60:1900; the complex minerals are a mixture of calcium carbonate, zinc gluconate and magnesium gluconate in a mass ratio of 1:3:1.

[0064] In Comparative Examples 1-7, the preparation method of the Ganoderma lucidum extract used is as follows:

[0065] (1) Ganoderma lucidum fruiting bodies are crushed into Ganoderma lucidum particles with a particle size of 0.1-1 cm.

[0066] (2) Organic solvent extraction: The obtained Ganoderma lucidum particles were mixed with 7 times the mass of tetrahydrofuran, refluxed for 2.5 hours, and filtered. Repeated twice and the filtrates were combined.

[0067] (3) Ethanol-water gradient extraction: The residue obtained by organic solvent extraction was mixed with 7 times the mass of ethanol, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of 75% ethanol aqueous solution, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of 40% ethanol aqueous solution, refluxed for 2.5 h, and filtered; the residue was mixed with 7 times the mass of water, refluxed for 4 h, and the extraction with water was repeated twice. The filtrates were combined.

[0068] (4) combining all the filtrates obtained in the two steps of "organic solvent extraction" and "ethanol-water gradient extraction", standing to break the emulsion, and concentrating by rotary evaporation to recover the solvent. After concentrating until there is no alcohol taste, freeze-drying is performed to obtain the Ganoderma lucidum extract.

[0069] In the above-mentioned Examples 1-8 and Comparative Examples 1-7, the nutritional composition is obtained by uniformly mixing the components. The mixing order and mixing process of the components have no significant effect on the quality of the nutritional composition. For example, the nutritional composition in the above-mentioned Examples 1-8 and Comparative Examples 1-7 can be prepared by mechanically mixing the components.

[0070] Experimental example

[0071] The improvement effect of the nutritional compositions obtained in Examples 1-8 and Comparative Examples 1-7 on cachexia caused by liver cancer was evaluated.

[0072] 1. Experimental methods

[0073] 1.1. Construction of animal model of liver cancer cachexia

[0074] Modeling was performed with reference to the prior art article “Forebrain patterns of c-Fos and FosB induction during cancer-associated anorexia-cachexia in rat” (European Journal of Neuroscience, 2005, Vol. 21, pp. 2752-2766).

[0075] Male Buffalo rats weighing between 190 and 220 g were used for the experiments.

[0076] McA RH7777 hepatoma cells were purchased from Shanghai Yaji Biotechnology Co., Ltd. and cultured and expanded as follows.

[0077] The temperature of the cell culture incubator is 37°C, and the atmosphere is 95% air + 5% carbon dioxide filtered sterile gas. DMEM medium containing 10% volume concentration of fetal bovine serum and 1% volume concentration of penicillin-streptomycin mixed solution is used for cell culture. McA RH7777 is a semi-adherent cell. When the cells in the cell culture dish occupy about 70% of the culture dish area and there is a semi-detached monolayer of cells, it is necessary to pass the cells. The passaging ratio is between 1:4 and 1:6, and the cells are passed once a week.

[0078] The rats were randomly divided into groups, with 5 rats in each group. The blank control group was subcutaneously injected with sterile saline, and the modeling rats were subcutaneously injected with sterile PBS solution of McA RH7777 liver cancer cells (10 7 McARH7777 liver cancer cells). After the injection of tumor cells for modeling, the body weight of each rat was recorded (the day after injection was designated as day 0 after injection), and the relative body weight of each rat compared with day 0 after injection was calculated.

[0079] Relative body weight = rat body weight on the i-th day of injection ÷ rat body weight on the 0th day of injection × 100%, wherein the value of i is an integer greater than or equal to 1.

[0080] From the 0th day to the 14th day after injection, the blank control rats and the modeling rats were free to eat the same rat support diet. Starting from the 15th day after subcutaneous injection of tumor cells, the body weight of the liver cancer modeling rats showed a significant downward trend, indicating that the liver cancer cachexia model was successfully modeled. Starting from the 15th day after subcutaneous injection of tumor cells, the modeling rats were grouped and the feeding method was adjusted.

[0081] 1.2 Experimental Grouping

[0082] The experimental groups are as follows:

[0083] Blank control group: subcutaneous injection of normal saline, free access to rat support feed.

[0084] Modeling control group: tumor cells were injected subcutaneously and rats were fed with supportive diet freely.

[0085] Oral gavage control group: tumor cells were injected subcutaneously, and the rats were free to eat rat support feed from day 0 to day 14 after injection. Starting from day 15 after injection, rat support feed was administered by oral gavage at 10 g / kg / day (based on the dry weight of rat support feed, the rat support feed was crushed and mixed with an appropriate amount of water to form a suspension for oral gavage) on the basis of free access to rat support feed.

[0086] Example group / comparative example group: subcutaneous injection of tumor cells, free access to rat support feed from day 0 to day 14 after injection, and from day 15 after injection, free access to rat support feed, daily gavage of 10 g / kg / day of the composition provided by the example group / comparative example group (based on the dry weight of the rat support feed, the composition was mixed with an appropriate amount of water to form a suspension for gavage).

[0087] 2. Experimental results

[0088] 2.1. Changes in rat body weight

[0089] The mean and standard deviation of the relative body weight of rats in the blank control group and the modeling control group on the 2nd day after injection and the 15th day after injection (the 1st day of gavage) are shown in the following table (n=5, mean±standard deviation):

[0090] Group Relative body weight on the second day after injection (%) Relative body weight on day 15 after injection (%) Blank control group 102.28±0.148 109.12±0.136 Modeling control group 102.05±0.180 <![CDATA[106.71±0.243 a ]]>

[0091] Among them, the superscript a indicates that the relative body weight of the modeling control group 15 days after injection is significantly different from that of the blank control group, and the p value is <0.001.

[0092] As can be seen from the data in the table above, on the second day after injection, tumor cells entered the rats but had not yet developed, and cachexia did not appear in the modeling group. On the 15th day after injection, tumor cells entered the rats and developed rapidly, and the body weight of the modeling rats was significantly lower than that of the blank control, indicating that the liver cancer cachexia model was successfully established.

[0093] The mean and standard deviation of the relative body weight of rats in each group on the 20th day after injection (the 6th day after oral administration) are shown in the following table (n=5, mean±standard deviation):

[0094]

[0095]

[0096] Among them, the superscript ## Indicates significant difference compared with the gavage control group, and p < 0.01; ### Indicates significant difference compared with the gavage control group, and p < 0.001; #### Indicates significant difference compared with the gavage control group, and p < 0.0001. * Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.05; superscript *** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.001; superscript ****Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with the Example 1 group, and p < 0.0001.

[0097] The mean and standard deviation of the relative body weight of rats in each group on the 25th day after injection (the 11th day after oral administration) are shown in the following table (n=5, mean±standard deviation):

[0098]

[0099]

[0100] Among them, the superscript ## Indicates significant difference compared with the gavage control group, and p < 0.01; ### Indicates significant difference compared with the gavage control group, and p < 0.001; #### Indicates significant difference compared with the gavage control group, and p < 0.0001. ** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.01; superscript *** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.001; superscript **** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with the Example 1 group, and p < 0.0001.

[0101] The mean and standard deviation of the relative body weight of rats in each group on the 30th day after injection (16th day after oral administration) are shown in the following table (n=5, mean±standard deviation):

[0102]

[0103]

[0104] Among them, the superscript # Indicates significant difference compared with the gavage control group, and p < 0.05; ## Indicates significant difference compared with the gavage control group, and p < 0.01; ### Indicates significant difference compared with the gavage control group, and p < 0.001; #### Indicates significant difference compared with the gavage control group, and p < 0.0001. ** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.01; superscript ***Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with Example 1, and p < 0.001; superscript **** Representative Examples 2 to 8 and Comparative Examples 1 to 7 have significant differences compared with the Example 1 group, and p < 0.0001.

[0105] It can be seen that after 16 days of gavage, there was no significant difference between the modeling control group and the gavage control group, and the modeling control group was significantly lower than the blank control group of rats with non-liver cancer cachexia. This shows that although the rats were supplemented with additional nutrients by gavage of maintenance feed, this supplement could not maintain or significantly increase the weight of the rats, that is, it had no obvious effect on improving rat liver cancer cachexia.

[0106] After 16 days of gavage, the body weight data of Examples 1-8 were significantly higher than those of the gavage control group, which shows that the nutritional composition provided by Examples 1-8 has a significant effect on improving the body weight of rats with liver cancer cachexia, and effectively improves the symptoms of weight loss in rats with liver cancer cachexia. Compared with the gavage control group, the weight of rats in Comparative Examples 1-7 was increased to a certain extent, but not as high as the increase in the weight of rats in Examples 1-8. In particular, compared with Comparative Examples 1-7, the weight of rats in Example 1 was significantly higher, which shows that for rats with liver cancer cachexia, continuous administration of the nutritional composition provided by Example 1 has a significantly better effect of improving the weight of rats with liver cancer cachexia.

[0107] 2.2. Detection of serum albumin (ALB) and hemoglobin (HGB) concentrations in rats

[0108] After body weight was measured on the 16th day of intragastric administration, venous blood was collected from the inner canthus of each group of rats to detect the concentrations of serum albumin (ALB) and hemoglobin (HGB). The test results are shown in the following table (n=5, mean ± standard deviation):

[0109]

[0110]

[0111] It can be seen that compared with the nutritional compositions provided in Comparative Examples 1 to 7, the nutritional compositions provided in Examples 1 to 8 have the function of better improving the phenomenon of decreased serum albumin and decreased hemoglobin caused by liver cancer cachexia in rats.

[0112] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A nutritional composition for nutritional support of liver cancer patients, characterized in that: Includes the following ingredients: Valine, lysine, peanut peptide powder, mung bean peptide powder, whey protein powder, maltodextrin, black rice powder, resistant dextrin, soy lecithin, medium chain triglycerides, multivitamins, multiminerals, selenium yeast powder, gardenia extract, ginkgo powder and ganoderma extract.

2. The nutritional composition according to claim 1, characterized in that The following ingredients are included by mass: 3.1-3.5 parts of valine, 0.8-1.2 parts of lysine, 1.6-2.4 parts of peanut peptide powder, 1.6-2.4 parts of mung bean peptide powder, 28-42 parts of whey protein powder, 14-19.6 parts of maltodextrin, 7-9.8 parts of black rice powder, 14-19.6 parts of resistant dextrin, 2-3 parts of soybean lecithin, 2-3 parts of medium-chain triglycerides, 0.6-0.8 parts of multivitamins, 0.9-1.1 parts of multiminerals, 0.5-1.5 parts of selenium yeast powder, 1-3 parts of gardenia extract, 0.5-1.5 parts of ginkgo powder and 1-3 parts of ganoderma lucidum extract; Wherein, the compound vitamin is a mixture of vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C; The composite mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate.

3. The nutritional composition according to claim 2, characterized in that The following ingredients are included by mass: 3.2-3.4 parts of valine, 0.9-1.1 parts of lysine, 1.8-2.2 parts of peanut peptide powder, 1.8-2.2 parts of mung bean peptide powder, 32-38 parts of whey protein powder, 15.6-18 parts of maltodextrin, 7.8-9 parts of black rice flour, 15.6-18 parts of resistant dextrin, 2.2-2.8 parts of soybean lecithin, 2.2-2.8 parts of medium-chain triglycerides, 0.65-0.75 parts of complex vitamins, 0.95-1.05 parts of complex minerals, 0.75-1.25 parts of selenium yeast powder, 1.5-2.5 parts of gardenia extract, 0.75-1.25 parts of ginkgo powder and 1.5-2.5 parts of ganoderma lucidum extract.

4. The nutritional composition according to claim 3, characterized in that The following ingredients are included by mass: 3.3 parts of valine, 1 part of lysine, 2 parts of peanut peptide powder, 2 parts of mung bean peptide powder, 35 parts of whey protein powder, 16.8 parts of maltodextrin, 8.4 parts of black rice powder, 16.8 parts of resistant dextrin, 2.5 parts of soybean lecithin, 2.5 parts of medium-chain triglycerides, 0.7 parts of multivitamins, 1 part of multiminerals, 1 part of selenium yeast powder, 2 parts of gardenia extract, 1 part of ginkgo powder and 2 parts of ganoderma lucidum extract.

5. The nutritional composition according to claim 1, characterized in that The mass ratio of the maltodextrin, the resistant dextrin and the black rice flour is 2:2:

1.

6. The nutritional composition according to claim 1, characterized in that The preparation method of the ganoderma lucidum extract comprises the following steps: S1, mixing Ganoderma lucidum with water, refluxing for extraction, and filtering to obtain filtrate A and residue A; S2, mixing the filter residue A with tetrahydrofuran, reflux extraction, and filtering to obtain filtrate B and filter residue B; S3, subjecting the filter residue B obtained in step S2 to ethanol-water gradient extraction, and combining the filtrates obtained by the gradient extraction to obtain filtrate C; S4, combining the filtrate A obtained in step S1, the filtrate B obtained in step S2 and the filtrate C obtained in step S3, concentrating and drying to obtain a Ganoderma lucidum extract.

7. The nutritional composition according to claim 1, characterized in that The preparation method of the gardenia extract comprises the following steps: The gardenia is crushed, mixed with 1-2 times the weight of water, simmered for 2-3 hours, filtered, and the filtrate is freeze-dried to obtain freeze-dried powder of the filtrate. 10% of the weight of the filter residue is freeze-dried and ground into powder, and mixed with the freeze-dried powder of the filtrate to obtain the gardenia extract.

8. The nutritional composition according to claim 2, characterized in that The compound vitamins are vitamin A, vitamin D, vitamin E, vitamin B1, vitamin B2, vitamin B6, niacin, folic acid, pantothenic acid and vitamin C according to 18-20: The mixture is mixed in a mass ratio of 0.01-0.05:130:20-30:20-30:20-30:250:4:60:1900-2000.

9. The nutritional composition according to claim 2, characterized in that The composite mineral is a mixture of calcium carbonate, zinc gluconate and magnesium gluconate in a mass ratio of 1:2-3:1-2.

10. A nutritional support product prepared using the nutritional composition according to any one of claims 1 to 9 as a raw material.

11. The nutritional support product according to claim 10, characterized in that: The dosage form of the nutritional support product is powder.

12. Use of the nutritional composition according to any one of claims 1 to 9 in producing a product for nutritional support of liver cancer patients.

Images